细胞凋亡和代谢基因在转移倾向结肠癌中的研究

目的:应用基因微阵列技术初步筛选与不同转移倾向结肠癌相关的细胞凋亡和代谢相关基因,研究转移相关基因功能.方法:取结肠癌肝转移和无转移结肠癌组织,采用人全基因组表达谱芯片获得两组织的基因表达谱,分析比较两者之间细胞凋亡和代谢基因的差异表达情况;利用基因数据库检索结肠癌相关基因,分析基因功能.结果:应用含有16450个克隆(其中3869个未知)的cDNA微阵列分析发现,细胞凋亡或肿瘤相关基因中,2倍以上(Ratio值小于0.5或大于2.0)差异基因共216个,上调基因85个,下调基因129个.表达差异5倍以上(Ratio值小于0.2或大于5.0)共32个,上调基因10个,下调基因22个.在细胞代谢相关基因中,2倍以上(Ratio值小于0.5或大于2.O)差异基因共205个,上调基因86个,下调基因119个.表达差异5倍以上(Ratio值小于0.2或大于5.0)共15个,上调基因10个,下调基因5个.利用基因数据库检索分析发现5个基因与结肠癌转移关系密切.结论:结肠癌的发生和转移是多基因参与的,本实验应用基因微阵列技术发现细胞凋亡和代谢相关基因中发现5个基因与结肠癌转移关系密切.     

左右半结肠癌多组学分子特征差异的研究进展

结肠癌(colon cancer,CC)是一种常见的恶性肿瘤,其发病率和死亡率均占癌症前列。根据解剖学位置,CC可分为左半结肠癌(left-sided colon cancer,LCC)和右半结肠癌(right-sided colon cancer,RCC),两者在临床特征上表现出较大的差异。近些年来,随着生物学技术和测序技术的发展,从多组学角度分析LCC和RCC分子特征和微环境差异的研究也越来越多,从而来揭示患者预后并指导其治疗。该文从基因突变、基因表达、miRNA表达、DNA甲基化、免疫微环境、共识分子亚型以及免疫治疗这几个方面来阐述LCC和RCC在分子特征和治疗差异上的研究进展。     

结肠癌组织RASSF1A基因转录表达和启动子区甲基化研究

目的:研究Ras相关区域家族1A基因(ras association domain family 1A,RASSF1A)启动子区甲基化对结肠癌组织中该基因转录和表达的影响.方法:应用甲基化特异性PCR(Methylation-special PCR,MSP)、RT-PCR和Western blot方法检测30例结肠癌组织和癌旁组织中的RASSF1A基因启动子区甲基化状态、mRNA和蛋白表达水平.结果:①RASSF1A基因启动子区在结肠癌纽织和正常组织中的甲基化频率分别为57%(17/30)和20%(6/30),甲基化频率在两组具有统计学差异(p＜0.01),,结肠癌组织中RASSF1A基因启动子区甲基化频率显著高于癌旁正常组织(x2=8.531,p＜0.01);②结肠癌组织中RASSF1A基因mRNA和蛋白袁达均显著低于癌旁组织(癌组织和癌旁正常组织中mRNA相对表达量分别为0.2836±0.0493和0.5092±0.0433,P＜0.001;以上组织中蛋白相对表达量分别为0.3124±0.0472和0.5320±0.0440,P＜0.01);③在结肠癌组织中,甲基化组RASSF1A基因mRNA和蛋白表达明显低于非甲基化组(甲基化组和非甲基化组mRNA相对表达量分别为0.0686±0.0174和0.5511±0.0486,P＜0.0001;以上组中蛋白相对表达量分别为0.1219±0.0326和0.5614±0.0380,P＜0.0001).结论:结肠癌组织中RASSF1A基因启动子区甲基化明显增高,与该基因蛋白表达减少显著相关,这可能是导致结肠癌中RASSF1A抑癌基因失活的主要因为.     

临床手术治疗结肠癌合并肠梗阻的疗效观察

目的:分析临床手术治疗结肠癌合并肠梗阻的疗效。方法:回顾性分析我院收治的72例结肠癌合并肠梗阻患者的临床资料,并观察手术治疗的效果。结果:72例患者行急诊手术24例,并发症发生率37.5%,行择期手术48例,并发症发生率7.14%,急诊手术并发症发生率明显高于择期手术(P0.05);47例左半结肠癌患者并发症发生率23.04%,25例右半结肠癌患者并发症发生率4.0%,左半结肠癌患者并发症发生率明显高于右半结肠癌患者(P0.05)。结论:手术治疗结肠癌合并肠梗阻时应根据具体情况确定合理的手术时机及手术方式,做好并发症预防,以最大限度减少手术创伤。     

PDIA1和EF1D在左侧和右侧结肠癌差异表达的实验研究

目的：初步确定蛋白质二硫化异构酶A1和延伸因子1-delta为左侧和右侧结肠癌中差异表达蛋白,为左侧和右侧结肠癌在肿瘤生物学方面的差异提供分子遗传学依据。方法：收集人左侧结肠癌（LSCC）和右侧结肠癌（RSCC）组织标本,进行二维凝胶电泳、质谱分析和生物信息学分离和鉴定左右侧结肠癌中差异表达蛋白质,进一步应用RT—PCR、WesternBlot和免疫组织化学技术检测蛋白质二硫化畀构酶A1和延伸因子1-delta在左侧和右侧结肠癌中的表达状态。结果：筛选并成功鉴定出左侧和右侧结肠癌中16种差异表达蛋白质,与右侧结肠癌比较,lO种蛋白在左侧结肠癌表达上调,6种蛋白在左侧结肠癌表达下调,其中蛋白质二硫化异构酶A1在左侧结肠癌中表达上调,延伸因子1-delta在左侧结肠癌中表达下调,并通过RT-PCR、Western Blot和免疫组化方法证实了在左侧和右侧结肠癌中该两种蛋白表达的差异,与蛋白质组学结果一致。结论：左侧结肠癌和右侧结肠癌的蛋白质组存在差异,其中蛋白质二硫化异构酶A1和延伸因子1—delta在mRNA和蛋白水平均存在差异,这些可能是左侧和右侧结肠癌生物学行为差异的原因。     

PDIA1 和EF1D 在左侧和右侧结肠癌差异表达的实验研究

目的:初步确定蛋白质二硫化异构酶A1和延伸因子1-delta为左侧和右侧结肠癌中差异表达蛋白,为左侧和右侧结肠癌在肿瘤生物学方面的差异提供分子遗传学依据。方法:收集人左侧结肠癌(LSCC)和右侧结肠癌(RSCC)组织标本,进行二维凝胶电泳、质谱分析和生物信息学分离和鉴定左右侧结肠癌中差异表达蛋白质,进一步应用RT-PCR、Western Blot和免疫组织化学技术检测蛋白质二硫化异构酶A1和延伸因子1-delta在左侧和右侧结肠癌中的表达状态。结果:筛选并成功鉴定出左侧和右侧结肠癌中16种差异表达蛋白质,与右侧结肠癌比较,10种蛋白在左侧结肠癌表达上调,6种蛋白在左侧结肠癌表达下调,其中蛋白质二硫化异构酶A1在左侧结肠癌中表达上调,延伸因子1-delta在左侧结肠癌中表达下调,并通过RT-PCR、Western Blot和免疫组化方法证实了在左侧和右侧结肠癌中该两种蛋白表达的差异,与蛋白质组学结果一致。结论:左侧结肠癌和右侧结肠癌的蛋白质组存在差异,其中蛋白质二硫化异构酶A1和延伸因子1-delta在mRNA和蛋白水平均存在差异,这些可能是左侧和右侧结肠癌生物学行为差异的原因。     

miR-223在结肠癌组织中的表达及促进结肠癌细胞迁移侵袭的机制研究

目的:探讨微小RNA-223 (mi R-223)在结肠癌组织中的表达及对结肠癌HT-29细胞侵袭、迁移能力的影响及机制。方法:检测mi R-223在结肠癌组织与癌旁组织中的表达。通过脂质体转染法将mi R-223模拟物(mi R-223 mimics,mi R-223 mimics组)及microRNA无关序列(mi R-223 NC,NC组)转染入结肠癌HT-29细胞。采用Real-time PCR检测转染后细胞中mi R-223和TWIST的表达,Western blot检测TWIST的蛋白表达,Tranwell检测细胞的迁移与侵袭能力。双荧光素酶报告基因检测mi R-223对TWIST基因启动子活性的影响。采用Transwell迁移与侵袭实验检测mi R-223 mimic及Twist si RNA共转染后人结肠癌细胞系HT-29迁移与侵袭能力的变化。结果:与癌旁结肠组织比较,mi R-223在结肠癌组织中呈现明显高表达(P0.05);与空白对照组和mi R-223 NC组比较,转染mi R-223 mimics后的HT-29细胞中的mi R-223表达显著增加(P0.05)。与阴性对照组和空载转染组相比较,mi R-223 mimics转染组穿透的细胞数目明显增加(P0.05),且mi R-223 mimics转染组的细胞侵袭能力显著增强(P0.05)。与mi R-223 NC组和空白对照组比较,转染mi R-223 mimics的HT-29细胞的TWIST基因m RNA和蛋白表达均显著增加(P0.05)。双荧光素酶检验结果显示TWIST为mi R-223的下游靶基因。共转染TWIST si RNA和mi R-223 mimics的结肠癌HT-29细胞的迁移与侵袭能力较单独转染mi R-223 mimics的HT-29细胞显著减弱(P0.05)。结论:mi R-223可能通过上调下游靶基因TWIST水平促进结肠癌HT-29细胞的迁移与侵袭。     

S100A4基因在结肠癌中的表达及意义

目的：通过检测S100A4基因在结肠癌细胞系及结肠癌组织中的表达,探讨其与结肠癌的关系。方法：运用RT-PCR法检测不同结肠癌细胞系中S100A4基因的表达情况;通过原位杂交和免疫组化方法检测61例结肠癌标本中S100A4基因的表达。结果：结肠癌细胞系Lovo及HT29均有S100A4基因表达。S100A4蛋白和RNA在结肠癌中表达率分别为36．1％和34.4％,而在正常结肠组织中不表达（p〈0．05）。临床分期晚比临床分期早的患者S100A4表达明显增高（p〈0.05）;有淋巴结转移的患者比无淋巴结转移的患者S100A4表达明显增高（p〈0．05）。此外,S100A4表达还与肿瘤大小,病理学分级,肉眼分型等相关。结论：结肠癌中S100A4基因表达增高,而且与肿瘤的侵袭及转移密切相关,是判断结肠癌生物学行为及预后的有价值的指标。     

不同原发肿瘤位置对于西妥昔单抗联合化疗治疗K-ras 基因 野生型的转移性结直肠癌患者的预后比较

目的:探讨不同原发肿瘤位置对于西妥昔单抗治疗K-ras基因野生型的转移性结直肠癌患者的预后影响。方法:回顾性分析2008年1月1日至2013年12月31日187例我院行西妥昔单抗联合FOLFOX或FOLFIRI治疗的转移性结直肠癌患者,根据原发肿瘤位置,以结肠左曲为分界点分为右半结肠癌和左半结肠癌两组,按照严格的配对标准进行1:2配对,最终获得右半结肠癌组16例,左半结肠癌组32例,进行分析,比较两组患者的近期疗效和无进展生存期。结果:右半结肠癌组ORR为56.3%,左半结肠癌组ORR为62.5%,2组比较差异无统计学意义(X2=0.174,P=0.676)。右半结肠癌组DCR为87.5%,左半结肠癌组DCR为93.7%。2组比较差异无统计学意义(X2=0.545,P=0.460)。右半结肠癌组的中位无进展生存时间(m PFS)为5.0个月,左半结肠癌组mPFS为7.7个月,两组差别有统计学意义(P0.05)。结论:K-Ras基因野生型的左半结肠癌患者应用西妥昔单抗治疗,预后好于右半结肠癌。     

A new human colon carcinoma line

Supported by the “Tumorzentrum Heidelberg-Mannheim”.     

Fucosyltransferase III and sialyl-Lex expression correlate in cultured colon carcinoma cells but not in colon carcinoma tissue

The potential contribution of fucosyltransferases to the overexpression of sialyl-Le^x antigen was investigated in the colon carcinoma cell line HT-29 and in human colon carcinoma tissue. In HT-29 cells as well as in normal or malignant colonic tissues Fuc-TIII, Fuc-TIV, Fuc-TVI but not Fuc-TV nor Fuc-TVII were detectable after RT-PCR. Sodium butyrate treatment of HT-29 cells increased (to about 200%) and DMSO treatment decreased (to about 20%) the expression of sialyl-Le^x. This modulation of sialyl-Le^x was concomitant with the analogous increase/decrease of mRNA of Fuc-TIII but not Fuc-TIV. Fuc-TVI was not detectable by Northern blotting in HT-29 cells. In six human colon carcinomas which exhibited strong overexpression of sialyl-Le^x, the expression of Fuc-TIII-mRNA was the same or lower than in the corresponding normal colonic tissue. Thus Fuc-TIII expression may be affecting the expression of the sialyl-Le^x moiety in HT-29 cells but not in human colon carcinoma tissue.     

OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders

The OVX1 tumor marker promises to complement CA125 for detection of early stage ovarian carcinoma. OVX1 has also been shown to be elevated in colon cancer patients. This study is designed to assess serum OVX1 levels in patients with specific stages of colon cancer, colon polyps or other GI disorders. Serum OVX1 and CEA were measured by radioimmunoassay or enzyme immunoassay for 206 patients at the time of colonoscopy or staging for colon carcinoma. In patients with stage I, II, III, or IV colon carcinoma, serum OVX1 was positive in 37%, 48%, 74% and 63%, respectively. Fifty-three percent of patients with colon polyps had elevated OVX1 levels, while OVX1 levels were positive in only 7% of healthy controls. If both OVX1 and CEA were considered, at least one of these markers was elevated in 36%, 60%, 79% or 89% of patients with stage I, II, III or IV colon carcinoma, respectively. The majority of patients with inflammatory bowel disease or diverticulosis also had elevated OVX1 levels. Both markers were positive in 27% of patients with colon carcinoma, and not in any patients with a normal colonoscopy or with a diagnosis of diverticulosis or hemorrhoids. In conclusion, serum OVX1 improves the sensitivity of CEA for detecting colon polyps and colon cancer; however, the use of OVX1 in this setting is hindered by its elevation in non-malignant colonic processes.     

Cytotoxic effect of gossypol on colon carcinoma cells

Gossypol, a male contraceptive drug extracted from cottonseeds, has been found to have antiproliferative activity on tumour cells and is thought to be a potential anticancer drug. The aim of this study was to investigate the mechanisms of gossypol-induced cell death on two colon carcinoma cell lines, HT29 and LoVo. Firstly, we studied the effect of gossypol on the colony forming ability of these tumour cells, which is the main target of chemotherapeutic drugs. Using clonogenic assays, flow cytometry and DNA gel electrophoresis techniques, we have found that gossypol not only inhibited colony forming ability of these tumour cells, but we also observed cellular internucleosomal DNA fragmentation in the cells treated with 3 doses of gossypol and this was accompanied by the appearance of a sub-G1 apoptotic peak and morphological characteristics of apoptosis. Our results suggest that the gossypol induced cell death is via an apoptotic pathway and the effect of gossypol may not be cell cycle specific. Using Western blotting analysis, we found that the gossypol-induced apoptosis may not be involved in the regulation of p53 but possibly associated with the regulation of bcl-2 and Bax expression. Our evidence indicates that gossypol may provide a potential therapeutic benefit for the treatment of colon carcinoma and understanding the mechanisms of gossypol-induced cytotoxicity on tumour cells is essential for including this drug in clinical use.     

Bisnaphthalimidopropyl spermidine induces apoptosis within colon carcinoma cells

Bisnaphthalimido compounds bisintercalate to DNA via the major groove and are potentially potent cancer therapeutics. We incorporated natural polyamines as linkers connecting the two-naphthalimido ring moieties to create a series of novel soluble cytotoxic bisnaphthalimidopropyl polyamines (BNIPPs). Here, we determined the cytotoxicity of bisnaphthalimidopropyl spermidine (BNIPSpd) towards Caco-2 and HT-29 colon adenocarcinoma cells revealing an IC₅₀ value of 0.15 and 1.64 μM after 48 h exposure within Caco-2 and HT-29 cells, respectively. After 4 h, ≥0.5 μM BNIPSpd treatment-induced significant DNA damage. After 24 h exposure a concentration-dependent increase in active caspase-3 expression, chromatin condensation and internucleosomal DNA fragmentation identified apoptosis as the principal manifestation for the cytotoxicity within both cell lines. By 24 h exposure, there was also a significant decline in cellular spermine and spermidine levels. It is concluded that bisnaphthalimidopropyl spermidine (BNIPSpd) toxicity primarily results from apoptosis and that BNISpd has potential to be further developed as an anti-tumour agent.